Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
Holding TCRX?
Track your performance easily
TCRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.73 - $9.69
Previous Close$5.7
Volume323.22K
Average Volume (3M)225.46K
Market Cap
$301.95M
Enterprise Value$121.19M
Total Cash (Recent Filing)$271.12M
Total Debt (Recent Filing)$90.36M
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Mar 05, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding52,973,870
10 Day Avg. Volume367,623
30 Day Avg. Volume225,464
Standard Deviation0.27
R-Squared0.02
Alpha0.00683
Financial Highlights & Ratios
Price to Book (P/B)1.12
Price to Sales (P/S)24.75
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue12.94
Enterprise Value/Gross Profit5.76
Enterprise Value/Ebitda-1.18
Forecast
1Y Price Target
$12.67Price Target Upside133.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
TScan Therapeutics News
PremiumCompany Announcements
TScan Therapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Leadership Changes and Stockholder Decisions at TScan Therapeutics
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyTScan's heme program continues to deliver essentially best-case scenario efficacy and safety data.
Financial PositionThe company is well positioned through several key inflection points and into Q4 2026 with $271.1M in cash, cash equivalents, and marketable securities.
Innovative ApproachTScan's proposed multiplexing approach, which combines TCR-Ts against multiple targets, is a key differentiator from competitors.
Bears Say
Competitive PressureThere are competing PRAME targeting programs from other companies, suggesting a competitive landscape.
Market PositionTScan's initial multiplex data is expected in 2025, which may delay competitive positioning in the market.
Safety ConcernsTwo non relapse/non treatment-related deaths occurred in the treatment arm.
---
Ownership Overview
16.28% Insiders
7.94% Mutual Funds
5.31% Other Institutional Investors
60.35% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $3.73 and its highest was $9.69 in the past 12 months.
What is TScan Therapeutics’s market cap?
Currently, no data Available
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Mar 05, 2025 which is in 103 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.315 by $0.065.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -$0.31.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 48,697,280 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.315. Following the earnings report the stock price went up 7.561%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Among the largest hedge funds holding TScan Therapeutics’s share is Baker Bros Advisors LP. It holds TScan Therapeutics’s shares valued at 16M.
---
TScan Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.67 (133.76% Upside)
$12.67 (133.76% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average 73%
Sector Average 73%
Hedge Fund Trend
Increased
By 163.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $869.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
27.23%
12-Months-Change
Fundamentals
Return on Equity
-46.84%
Trailing 12-Months
Asset Growth
18.28%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
---
TCRX Stock 12 Month Forecast
Average Price Target
$12.67
▲(133.76% Upside)
Technical Analysis
Best Analysts Covering TCRX
1 Year
1 Year Success Rate
6/11 ratings generated profit
1 Year Average Return
+32.63%
reiterated a buy rating 3 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +32.63% per trade.
---